Ethosuximide-d5

Ethosuximide-d5 is intended for use as an internal standard for the quantification of ethosuximide (Cay-23947) by GC- or LC-MS. Ethosuximide is an anticonvulsant. It increases glucose, fructose-1,6-bisphosphate, and pyruvate levels in rat brain when administered at a dose of 200 mg/kg. Ethosuximide (400 mg/kg) reduces the severity of audiogenic seizures in a rat model of barbiturate withdrawal-induced convulsions. It also inhibits tonic hindlimb extension induced by pentylenetetrazole (PTZ, Cay-18682) or brainstem stimulation (ED50s = 35 and 70 mg/kg, respectively), as well as leptazol-induced clonic seizures (ED50 = 230 mg/kg), in rats. Ethosuximide reduces resting tremor by 60% in a macaque model of Parkinson's disease induced by MPTP when administered at a dose of 150 mg/animal for 5 days. Formulations containing ethosuximide have been used in the treatment of petit mal seizures.Formal Name: 3-(ethyl-1,1,2,2,2-d5)-3-methyl-2,5-pyrrolidinedione. CAS Number: 1989660-59-4. Synonyms: CI-366-d5, NSC 64013-d5. Molecular Formula: C7H6D5NO2. Formula Weight: 146.2. Purity: >99% deuterated forms (d1-d5). Formulation: (Request formulation change), A solid. Solubility: Methanol: soluble. SMILES: O=C1CC(C([2H])([2H])C([2H])([2H])[2H])(C)C(N1)=O. InChi Code: InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)/i1D3,3D2. InChi Key: HAPOVYFOVVWLRS-WNWXXORZSA-N.